Loop diuretics: from the Na-K-2Cl transporter to clinical use

被引:113
作者
Shankar, SS [1 ]
Brater, DC [1 ]
机构
[1] Indiana Univ, Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA
关键词
edematous disorders; furosemide;
D O I
10.1152/ajprenal.00119.2002
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The diuretic response to loop diuretics in various disease states has consistently been found to be subnormal. One of the key determinants of the degree of diuretic response is the functional integrity of the sodium-potassium-chloride transporter in the loop of Henle. Studies in animal models suggest that expression/activity of the transporter may be affected by factors such as altered natural splicing events of NKCC2 (the gene encoding for the renal transporter), renal prostanoids, vasopressin, and other autacoids. We have reviewed the pharmacokinetics and pharmacodynamics of loop diuretics in health and in edematous disorders for which they are used. On the basis of evidence reviewed in this paper, we propose that altered expression or activity of the sodium-potassium-chloride transporter in the loop of Henle, in conjunction with events occurring in other segments of the nephron, possibly accounts for the altered diuretic response to these agents. Thus the modulators of this altered expression/activity could serve as important therapeutic targets for alternative diuretic regimens in these conditions.
引用
收藏
页码:F11 / F21
页数:11
相关论文
共 103 条
[1]  
Agarwal R, 2000, J AM SOC NEPHROL, V11, P1100, DOI 10.1681/ASN.V1161100
[2]  
Agre P, 2000, J AM SOC NEPHROL, V11, P764, DOI 10.1681/ASN.V114764
[3]   DIURETIC EFFECT OF FRUSEMIDE IN PATIENTS WITH NEPHROTIC SYNDROME - IS IT POTENTIATED BY INTRAVENOUS ALBUMIN [J].
AKCICEK, F ;
YALNIZ, T ;
BASCI, A ;
OK, E ;
MEES, EJD .
BRITISH MEDICAL JOURNAL, 1995, 310 (6973) :162-163
[4]  
ALMESHARI K, 1993, J AM SOC NEPHROL, V3, P1878
[5]   DISTRIBUTION, ELIMINATION AND EFFECT OF FUROSEMIDE IN NORMAL SUBJECTS AND IN PATIENTS WITH HEART-FAILURE [J].
ANDREASEN, F ;
MIKKELSEN, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (01) :15-22
[6]   BIOAVAILABILITY OF BUMETANIDE IN GROSSLY EDEMATOUS PATIENTS [J].
BAILIE, GR ;
GRENNAN, A ;
WALDEK, S .
CLINICAL PHARMACOKINETICS, 1987, 12 (06) :440-443
[7]  
BEERMANN B, 1977, CLIN PHARMACOL THER, V22, P70
[8]  
BEERMANN B, 1984, ACTA PHARMACOL TOX, V54, P17
[9]   Diuretic therapy [J].
Brater, DC .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :387-395
[10]   FUROSEMIDE IN PATIENTS WITH HEART-FAILURE - SHIFT IN DOSE-RESPONSE CURVES [J].
BRATER, DC ;
CHENNAVASIN, P ;
SEIWELL, R ;
BECK, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) :182-186